Ethical approval
Experimental protocols and procedures were approved by Chang Gung Memorial Hospitals Institutional Animal Care and Use Committee (No. 2019062002), Institutional Board Review (IRB: 201800954B0) and funded by the National Science and Technology Council Grants (MOST 107-2314-B-182A-103-). The study period took place from August 1st, 2018 to January 31st, 2020.
All procedures involving humans were carried out in accordance with relevant guidelines and regulations, and approved by Institutional Board Review Chang Gung Memorial Hospital. Informed consent was obtained from all participants/donor.
All experimental procedures were performed under the supervision of a licensed veterinarian, in a manner consistent with the regulations of the National Institute of Health of Taiwan. All animal related procedures were approved by the Institutional Animal Care and Use Committee of Chang Gung Memorial Hospital (IACUC Approval No.: CGMH2019062002). All methods involving animals are reported in accordance with ARRIVE guidelines.
The hAFSCs were obtained from freshly collected amniotic fluid by routine amniocentesis from healthy pregnant donors at 1520 gestational weeks. Cells were cultured in StemPro MSC Serum free medium supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad,CA) and incubated at 37C with 5% carbon dioxide. Culture medium was changed every 34days. The specific surface antigens of hAFSCs were characterized using flow cytometry analyses. The cultured cells were trypsinized and stained with phycoerythrin (PE)-conjugated antibodies against CD90 (BD PharMingen,CA). The cells were analyzed using the Calibur flow cytometer (Becton Dickinson, Heidelberg, Germany). Passage 4 to 6 hAFSCs were collected and prepared to a final concentration of 3106 cells/0.3mL Phosphate Buffer Solution (PBS). Thereafter, 3106 hAFSCs were seeded on a sterile mesh-scaffold and cultured for 3days prior transplantation. This is accordance to the previous work by Liang et al.12.
Three types of absorbable materials were compared, comprising AlloDerm RTM; PLGA mesh (VICRYL) and PDS mesh. The characteristic of each mesh is displayed in Table 1. Cell line from amniotic fluid stem cells was cultivated with basic fibroblast growth (bFGF). To measure the cells ability to proliferate, EdU Assay (Click-iTEdU Assay, Invitrogen, Life Technologies Corporation, Carlsbad, CA, USA) is incubated with hAFSC, and meshes-harvested with hAFSc. EdU Assay (5-ethynyl-2-deoxyuridine) works as a nucleoside analog of thymidine and is incorporated into DNA during active DNA synthesis. Procedure was performed in accordance to protocol (Supplementary, S1). DNA staining is performed for imaging and analysis. hAFSCs seeded mesh-scaffold were incubated at 37C in 5% CO2 for 60min, followed by Dulbeccos modified Eagle medium. MTS (5-(3-carboxymethoxyphenyl)-2-(4,5-dimethyl-thiazoly)-3-(4-sulfophenyl) tetrazolium, inner salt assay)13 colorimetric assay test were conducted on day 7 and day 14 for cell metabolic activity (Fig.1). DAPI (Santa Cruz Biotechnology, Santa Cruz, CA, USA) Stain for immunofluorescence imaging were also conducted on day 14. The most suitable mesh with hAFSC growth was determined by immunofluorescence assay and scanning electron microscopy (SEM) via LIVE/DEAD Viability/cytotoxicity Kit on day 7 and day 14. SEM enables direct microscopic imaging of the material properties on the surface sample, that offers adjustable magnification and large field depth. In this study, spot charge-coupled device color digital camera (Olympus DP72, Tokyo, Japan) was used to obtain immunohistochemistry images under 20objective (Olympus BX-51, Tokyo, Japan) and immunofluorescence under Leica TCS SP8X confocal laser scanning microscope (Leica Microsystem, Heidelberg, Germany) with appropriate filters for DAPI. Camera was interfaced with Image-Pro Plus Software (Media Cybernetics, Silver Spring, MD, USA). This is in accordance as previous study conducted by Liang et al.14.
Total of 28 SpragueDawley rats, with the mean age 12.31.7weeks old and weighing 298.227.1g were treated and cared for under the supervision of a licensed veterinarian, in a manner consistent with the regulations of the National Institute of Health of Taiwan. All animal related procedures were approved by the Institutional Animal Care and Use Committee of Chang Gung Memorial Hospital (IACUC Approval No.: CGMH2019062002).
Seven groups were assigned: [1] sham control group with fascia operation; [2] AlloDerm implant; [3] PDS implant; [4] PLGA implant; [5] AlloDerm harvest with hAFSC (AlloDerm-SC); [6] PDS harvest with hAFSC (PDS-SC); and [7] PGLA harvest with hAFSC (PGLA-SC).
Rats were anesthetized with 2% Isoflurane mask inhalation. An abdominal midline incision of 4cm and subcutaneous blunt dissection to muscle were made. A 1.01.0cm full-thickness abdominal muscle fascia resected. Mesh measuring 2.02.0cm was fixated with continuous, absorbable suture (Polygactin, Vicryl 3/0) to cover the defect. Skin was then closed with running subcuticular absorbable sutures (Vicryl 3/0) (Fig.2). Sham control group with fascia operation underwent abdominal muscle fascia resection without mesh implantation. In the present study, the number of control rats was reduced in compliance with IACUCs recommendation. Total of 12 rats (week 1), 4 rats (week 2) and 12 rats (week 12) were sacrificed at respective weeks. The tissues were harvested at 12weeks, and meshes were retrieved for tensile properties characteristic and immuno-histological examination.
The mechanical properties of three absorbable mesh with and without AFSC meshes were estimated utilizing tensile test equipment (Lloyd, Ametek, Berwyn, PA, USA) (Fig.3). The maximum strengths of three absorbable mesh with and without AFSC were compared. The stretching speed was set at 100mm/min and the ultimate load and deformation were recorded.
Tensiometry for mechanical properties of the scaffolds.
The rats were euthanized with 3% isoflurane and then decapitated, in accordance and manner consistent with the regulations of the National Institute of Health of Taiwan and Institutional Animal Care and Use Committee of Chang Gung Memorial Hospital.
Sample size calculation was done by using crude method based on law of diminishing return with the equation of E=total number of animals-total number of groups. After the calculation with (7 groups6 rats/group) (7groups)=35, suggesting the sample size for this study was adequate, and 6 rats were used for each group15. The data were analyzed and expressed as meanSD for continuous variables. Continuous data were compared among the groups by using one-way analysis of variance. To evaluate the effect of hAFSC among groups, chi-square test was performed with Fishers exact test. Probability value of<0.05 are statistically significant.
All procedures involving humans were carried out in accordance with relevant guidelines and regulations, and approved by Institutional Board Review Chang Gung Memorial Hospital. Informed consent was obtained from all participants/donor. All experimental procedures were performed under the supervision of a licensed veterinarian, in a manner consistent with the regulations of the National Institute of Health of Taiwan. All animal related procedures were approved by the Institutional Animal Care and Use Committee of Chang Gung Memorial Hospital (IACUC Approval No.: CGMH2019062002). All methods involving animals are reported in accordance with ARRIVE guidelines.
- International Stem Cell Corporation Provides Strategic Update on its Skin Care Program [Last Updated On: April 9th, 2010] [Originally Added On: April 9th, 2010]
- International Stem Cell Corporation Provides Strategic Update on its Skin Care Program [Last Updated On: April 9th, 2010] [Originally Added On: April 9th, 2010]
- CSC news roundup 2010-04-11 [Last Updated On: April 12th, 2010] [Originally Added On: April 12th, 2010]
- CSC news roundup 2010-04-11 [Last Updated On: April 12th, 2010] [Originally Added On: April 12th, 2010]
- International Stem Cell Corporation Engages Leading Immunogeneticists to Advance its Industry-first, Immune-matched Stem Cells [Last Updated On: April 14th, 2010] [Originally Added On: April 14th, 2010]
- International Stem Cell Corporation Engages Leading Immunogeneticists to Advance its Industry-first, Immune-matched Stem Cells [Last Updated On: April 14th, 2010] [Originally Added On: April 14th, 2010]
- MicroRNA therapy could be a powerful tool to correct the CSC dysregulation? [Last Updated On: April 17th, 2010] [Originally Added On: April 17th, 2010]
- MicroRNA therapy could be a powerful tool to correct the CSC dysregulation? [Last Updated On: April 17th, 2010] [Originally Added On: April 17th, 2010]
- CSC news links 2010-04-18 [Last Updated On: April 19th, 2010] [Originally Added On: April 19th, 2010]
- CSC news links 2010-04-18 [Last Updated On: April 19th, 2010] [Originally Added On: April 19th, 2010]
- Sessions on CSC Therapeutics at AACR10 [Last Updated On: April 27th, 2010] [Originally Added On: April 27th, 2010]
- Sessions on CSC Therapeutics at AACR10 [Last Updated On: April 27th, 2010] [Originally Added On: April 27th, 2010]
- CSC news links 2010-05-01 [Last Updated On: May 2nd, 2010] [Originally Added On: May 2nd, 2010]
- More about presentations at AACR10 [Last Updated On: May 2nd, 2010] [Originally Added On: May 2nd, 2010]
- More about presentations at AACR10 [Last Updated On: May 2nd, 2010] [Originally Added On: May 2nd, 2010]
- CSC news links 2010-05-01 [Last Updated On: May 2nd, 2010] [Originally Added On: May 2nd, 2010]
- International Stem Cell Corporation Signs Financing Agreement [Last Updated On: May 6th, 2010] [Originally Added On: May 6th, 2010]
- International Stem Cell Corporation Signs Financing Agreement [Last Updated On: May 6th, 2010] [Originally Added On: May 6th, 2010]
- CSC news links 2010-05-08 [Last Updated On: May 9th, 2010] [Originally Added On: May 9th, 2010]
- CSC news links 2010-05-08 [Last Updated On: May 9th, 2010] [Originally Added On: May 9th, 2010]
- International Stem Cell and Absorption Systems Confirm Results Showing Stem Cell Derived Corneal Tissue as an Alternative to Animals for Drug Testing [Last Updated On: May 12th, 2010] [Originally Added On: May 12th, 2010]
- International Stem Cell and Absorption Systems Confirm Results Showing Stem Cell Derived Corneal Tissue as an Alternative to Animals for Drug Testing [Last Updated On: May 12th, 2010] [Originally Added On: May 12th, 2010]
- Generic drug a potential treatment for glioblastoma? [Last Updated On: May 14th, 2010] [Originally Added On: May 14th, 2010]
- Generic drug a potential treatment for glioblastoma? [Last Updated On: May 14th, 2010] [Originally Added On: May 14th, 2010]
- US Patent: Isolation and use of solid tumor stem cells [Last Updated On: May 18th, 2010] [Originally Added On: May 18th, 2010]
- US Patent: Isolation and use of solid tumor stem cells [Last Updated On: May 18th, 2010] [Originally Added On: May 18th, 2010]
- International Stem Cell Corporation and The Automation Partnership Enter into Strategic Alliance to Automate Cornea Tissue Production [Last Updated On: May 19th, 2010] [Originally Added On: May 19th, 2010]
- International Stem Cell Corporation and The Automation Partnership Enter into Strategic Alliance to Automate Cornea Tissue Production [Last Updated On: May 19th, 2010] [Originally Added On: May 19th, 2010]
- An evolving concept of CSC in tumor biology [Last Updated On: May 21st, 2010] [Originally Added On: May 21st, 2010]
- An evolving concept of CSC in tumor biology [Last Updated On: May 21st, 2010] [Originally Added On: May 21st, 2010]
- International Stem Cell Corporation Moves International Cornea Development Program Forward [Last Updated On: May 26th, 2010] [Originally Added On: May 26th, 2010]
- International Stem Cell Corporation Moves International Cornea Development Program Forward [Last Updated On: May 26th, 2010] [Originally Added On: May 26th, 2010]
- Phase I clinical trial of ICT-107 [Last Updated On: June 3rd, 2010] [Originally Added On: June 3rd, 2010]
- Phase I clinical trial of ICT-107 [Last Updated On: June 3rd, 2010] [Originally Added On: June 3rd, 2010]
- CSCs responsible for metastasis identified [Last Updated On: June 6th, 2010] [Originally Added On: June 6th, 2010]
- CSCs responsible for metastasis identified [Last Updated On: June 6th, 2010] [Originally Added On: June 6th, 2010]
- International Stem Cell Corporation's Parthenogenetic Stem Cell Patent is Approved by the United States Patent and Trademark Office [Last Updated On: June 9th, 2010] [Originally Added On: June 9th, 2010]
- International Stem Cell Corporation's Parthenogenetic Stem Cell Patent is Approved by the United States Patent and Trademark Office [Last Updated On: June 9th, 2010] [Originally Added On: June 9th, 2010]
- International Stem Cell Corporation Announces Company Update Conference Call. ISCO Chairman Kenneth Aldrich to Discuss 'Status of the Company' [Last Updated On: June 10th, 2010] [Originally Added On: June 10th, 2010]
- International Stem Cell Corporation Announces Company Update Conference Call. ISCO Chairman Kenneth Aldrich to Discuss 'Status of the Company' [Last Updated On: June 10th, 2010] [Originally Added On: June 10th, 2010]
- Decitabine may target ovarian CSCs? [Last Updated On: June 14th, 2010] [Originally Added On: June 14th, 2010]
- Decitabine may target ovarian CSCs? [Last Updated On: June 14th, 2010] [Originally Added On: June 14th, 2010]
- New Article from North County Times - BIOTECH: International Stem Cell Clears Debt, Gets Patent [Last Updated On: June 17th, 2010] [Originally Added On: June 17th, 2010]
- New Article from North County Times - BIOTECH: International Stem Cell Clears Debt, Gets Patent [Last Updated On: June 17th, 2010] [Originally Added On: June 17th, 2010]
- Patent application: Levels of Oct1 as a method of identifying CSCs [Last Updated On: June 18th, 2010] [Originally Added On: June 18th, 2010]
- Patent application: Levels of Oct1 as a method of identifying CSCs [Last Updated On: June 18th, 2010] [Originally Added On: June 18th, 2010]
- OncoMed Has 'Wnt' in its Sails [Last Updated On: June 21st, 2010] [Originally Added On: June 21st, 2010]
- OncoMed Has 'Wnt' in its Sails [Last Updated On: June 21st, 2010] [Originally Added On: June 21st, 2010]
- International Stem Cell Corporation Names Charles J. Casamento to Board of Directors [Last Updated On: June 23rd, 2010] [Originally Added On: June 23rd, 2010]
- International Stem Cell Corporation Names Charles J. Casamento to Board of Directors [Last Updated On: June 23rd, 2010] [Originally Added On: June 23rd, 2010]
- International Stem Cell Corporation (ISCO.OB) Announces New Patent Issuance Under License Agreement [Last Updated On: June 25th, 2010] [Originally Added On: June 25th, 2010]
- International Stem Cell Corporation (ISCO.OB) Announces New Patent Issuance Under License Agreement [Last Updated On: June 25th, 2010] [Originally Added On: June 25th, 2010]
- California Health Institute Interviews Jeffrey Janus - CEO of Lifeline Cell Technology [Last Updated On: June 29th, 2010] [Originally Added On: June 29th, 2010]
- California Health Institute Interviews Jeffrey Janus - CEO of Lifeline Cell Technology [Last Updated On: June 29th, 2010] [Originally Added On: June 29th, 2010]
- International Stem Cell Corporation - Excerpt from Agora Financial's Breakthrough Technology Alert by Patrick Cox [Last Updated On: July 1st, 2010] [Originally Added On: July 1st, 2010]
- International Stem Cell Corporation - Excerpt from Agora Financial's Breakthrough Technology Alert by Patrick Cox [Last Updated On: July 1st, 2010] [Originally Added On: July 1st, 2010]
- Melanoma-initiating cells identified [Last Updated On: July 2nd, 2010] [Originally Added On: July 2nd, 2010]
- Melanoma-initiating cells identified [Last Updated On: July 2nd, 2010] [Originally Added On: July 2nd, 2010]
- International Stem Cell Corporation and Sankara Nethralaya Launch Collaboration to Develop Stem Cell-Based Treatment for Corneal Vision Impairment [Last Updated On: July 8th, 2010] [Originally Added On: July 8th, 2010]
- International Stem Cell Corporation and Sankara Nethralaya Launch Collaboration to Develop Stem Cell-Based Treatment for Corneal Vision Impairment [Last Updated On: July 8th, 2010] [Originally Added On: July 8th, 2010]
- Two recent OA articles [Last Updated On: July 12th, 2010] [Originally Added On: July 12th, 2010]
- Two recent OA articles [Last Updated On: July 12th, 2010] [Originally Added On: July 12th, 2010]
- Innovative Researcher Vlog [Last Updated On: July 16th, 2010] [Originally Added On: July 16th, 2010]
- Innovative Researcher Vlog [Last Updated On: July 16th, 2010] [Originally Added On: July 16th, 2010]
- More about salinomycin [Last Updated On: July 19th, 2010] [Originally Added On: July 19th, 2010]
- More about salinomycin [Last Updated On: July 19th, 2010] [Originally Added On: July 19th, 2010]
- International Stem Cell Corporation Plans $10 Million Financing Through European Subsidiary [Last Updated On: July 23rd, 2010] [Originally Added On: July 23rd, 2010]
- International Stem Cell Corporation Plans $10 Million Financing Through European Subsidiary [Last Updated On: July 23rd, 2010] [Originally Added On: July 23rd, 2010]
- Irradiating brain's stem cell niche [Last Updated On: July 26th, 2010] [Originally Added On: July 26th, 2010]
- Irradiating brain's stem cell niche [Last Updated On: July 26th, 2010] [Originally Added On: July 26th, 2010]
- Prostate CSCs sensitive to gamma-tocotrienol? [Last Updated On: July 27th, 2010] [Originally Added On: July 27th, 2010]
- Prostate CSCs sensitive to gamma-tocotrienol? [Last Updated On: July 27th, 2010] [Originally Added On: July 27th, 2010]
- Researchers Study CSCs as Therapeutic Targets for Mesothelioma [Last Updated On: July 28th, 2010] [Originally Added On: July 28th, 2010]
- Researchers Study CSCs as Therapeutic Targets for Mesothelioma [Last Updated On: July 28th, 2010] [Originally Added On: July 28th, 2010]
- International Stem Cell Corporation and Sristi Biosciences Enter Distribution Agreement for Lifeline Cell Technology's Brand of Human Cell Culture... [Last Updated On: July 29th, 2010] [Originally Added On: July 29th, 2010]
- Disagreement about melanoma CSCs [Last Updated On: July 29th, 2010] [Originally Added On: July 29th, 2010]
- International Stem Cell Corporation and Sristi Biosciences Enter Distribution Agreement for Lifeline Cell Technology's Brand of Human Cell Culture... [Last Updated On: July 29th, 2010] [Originally Added On: July 29th, 2010]
- Disagreement about melanoma CSCs [Last Updated On: July 29th, 2010] [Originally Added On: July 29th, 2010]
- Cell of origin for human prostate cancer [Last Updated On: August 1st, 2010] [Originally Added On: August 1st, 2010]
- Cell of origin for human prostate cancer [Last Updated On: August 1st, 2010] [Originally Added On: August 1st, 2010]